Evaluation of silibinin on the viability, migration and adhesion of the human prostate adenocarcinoma (PC-3) cell line

Cell Biology International

Volumn 32, Issue 8, 2008, Pages 888-892

  Mokhtari, Mohammad Javad ^a,b   Motamed, Nasrin ^b   Shokrgozar, Mohammad Ali ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Adhesion; Migration; PC 3; Silibinin; Viability

Indexed keywords

SILIBININ;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL ADHESION; CELL MIGRATION; CELL MOTILITY; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; PROSTATE ADENOCARCINOMA;

ADENOCARCINOMA; ANTIOXIDANTS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; PROSTATIC NEOPLASMS; SILYMARIN;

SILYBUM MARIANUM;

EID: 47549097718     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2008.03.019     Document Type: Article

References (31)

1. Chun S.C., Chiou H.L., Chen P.N., Yang S.F., and Hsieh Y.S. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol Carcinog 40 (2004) 143-149
2. Deep G., and Agarwal R. Chemopreventive efficacy of silymarin in skin and prostate cancer. Integr Cancer Ther 6 (2007) 130-145
3. Deep G., Singh R.P., Agarwal C., Kroll D.J., and Agarwal R. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC-3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene 25 (2006) 1053-1069
4. Evangelou A., Letarte M., Marks A., and J.Brown T. Androgen modulation of adhesion and antiadhesion molecules in PC-3 prostate cancer cells expressing androgen receptor. Endocrinology 143 (2002) 3897-3904
5. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 1 (2001) 34-45
6. Gazak R., Walterova D., and Kren V. Silybin and silymarin - new and emerging applications in medicine. Curr Med Chem 14 (2007) 315-338
7. Giancotti F.G., and Ruoslahti E. Integrin signaling. Science 285 (1999) 1028-1032
8. Gilles C., Polette M., Seiki M., Birembaut P., and Thompson E.W. Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. Lab Invest 76 (1997) 651-660
9. Humphries M.J., Olden K., and Yamada K.M. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 233 (1986) 467-470
10. Jiang C., Agarwal R., and Lu J. Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells. Biochem Biophys Res Commun 276 (2000) 371-378
11. Koivisto P., Kolmer M., Visakorpi T., and Kallioniemi O.P. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 152 (1998) 1-9
12. Kostenuik P.J., Sanchez-Sweatman O., Orr F.W., and Singh G. Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha 2 beta 1 integrin. Clin Exp Metastasis 14 (1996) 19-26
13. Liotta L.A., Rao C.N., and Wewer U.M. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem 55 (1986) 1037-1057
14. Nabeshima K., Inoue T., Shimao Y., and Sameshima T. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 52 (2002) 255-264
15. Neuhouser M.L. Dietary flavonoids and cancer risk: evidence from human population studies. Nutr Cancer 50 (2004) 1-7
16. Olaso E., Labrador J.P., Wang L., Ikeda K., Eng F.J., Klein R., et al. Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2. J Biol Chem 277 (2002) 3606-3613
17. Saller R., Meier R., and Bringnole R. The use of silymarin in the treatment of liver disease. Drugs 6 (2001) 2035-2063
18. Sharma G., Singh R.P., Chan D.C., and Agarwal R. Silibinin induces growth inhibition and apoptotic cell death in human lung carcinoma cells. Anticancer Res 23 (2003) 2649-2655
19. Singh R.P., Dhanalakshmi S., Tyagi A.K., Chan D.C., Agarwal C., and Agarwal R. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res 62 (2002) 3063-3069
20. Singh R.P., Tyagi A.K., Zhao J., and Agarwal R. Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis. Carcinogenesis 23 (2002) 499-510
21. Singh R.P., Sharma G., Dhanalakshmi S., Agarwal C., and Agarwal R. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev 12 (2003) 933-939
22. Surh Y.J. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3 (2003) 768-780
23. Tyagi A.K., Singh R.P., Agarwal C., Chan D.C., and Agarwal R. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. Clin Cancer Res 8 (2002) 3512-3519
24. Vollmers H.P., and Birchmeier W. Monoclonal antibodies that prevent adhesion of B 16 melanoma cells and reduce metastases in mice: cross reaction with human tumor cells. Proc Natl Acad Sci U S A 80 (1983) 6863-6867
25. Wagner H., Diesel P., and Seitz M. The chemistry and analysis of silymarin from Silybum marianum Gaertn. Arzneimittelforschung 24 (1974) 466-471
26. Wellington K., and Jarwis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 15 (2001) 465-489
27. Zali H., Rezaei-Tavirani M., Kariminia A., Yousefi R., and Shokrgozar M.A. Evaluation of growth inhibitory and apoptosis inducing activity of human calprotectin on the human gastric cell line (AGS). Iran Biomed J 12 (2008) 7-14
28. Zi X., and Agarwal R. Modulation of mitogen-activated protein kinase activation and cell cycle regulators by the potent skin cancer preventive agent silymarin. Biochem Biophys Res Commun 263 (1999) 528-536
29. Zi X., and Agarwal R. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc Natl Acad Sci USA 96 (1999) 7490-7495
30. Zi X., Grasso A.W., Kung H.J., and Agarwal R. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res 58 (1998) 1920-1929
31. Zi X., Zhang J., Agarwal R., and Pollak M. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 60 (2000) 5617-5620